Predict your next investment

Asset/Investment Management
karolinskadevelopment.com

See what CB Insights has to offer

Investments

37

Portfolio Exits

5

Funds

3

Partners & Customers

1

About Karolinska Development

Karolinska Development (STO: KDEV) is an investment company focused on identifying medical innovation and investing in the creation and growth of companies, developing these assets into differentiated products that will make a difference to patients' lives and provide an attractive return on investment.

Karolinska Development Headquarter Location

Tomtebodavagen 23 A

Solna, SE-17 165,

Sweden

+46 8 524 860 70

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Karolinska Development

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Karolinska Development in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Karolinska Development News

Karolinska Development's portfolio company OssDsign includes first patient to a clinical trial of the synthetic bone graft OssDsign Catalyst

Sep 9, 2021

Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company OssDsign AB has included the first patient to the clinical trial TOP FUSION which aims to evaluate the long-term safety and efficacy of the synthetic bone graft OssDsign Catalyst in patients undergoing spinal fusion surgery. The clinical trial will run for 24 months and include 17 patients suffering from degenerative disc disease, degenerative spondylolisthesis or lumbar spinal stenosis. TOP FUSION is being conducted primarily to evaluate the safety and efficacy of OssDsign Catalyst in patients undergoing spinal fusion surgery. Study outcomes are based primarily on the degree of fusion between the vertebrae and the incidence of treatment-related adverse events. The innovative bone graft consists of a patented nanocrystalline structure that is applied to the spine where it resorbs and is replaced by new bone tissue. The study is conducted under the leadership by Dr Péter Pál Varga and Dr Áron Lazary, internationally renowned physicians and researchers in spine surgery at the National Center for Spinal Disorders at the Buda Health Clinic in Budapest. Dr Varga is the founder of the specialist center where more than 2,500 spine surgeries are performed annually. “This is an important next step in the further validation of OssDsign Catalyst. Once again, OssDsign shows that they step by step are delivering on the commercialization plan set up for its innovative synthetic bone graft which was recently launched in the US,” comments Viktor Drvota, CEO, Karolinska Development AB. Karolinska Development's shareholding in OssDsign AB, including an indirect ownership via KCIF Co-Investment Fund, amounts to 10 per cent. For further information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders. Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success. Karolinska Development has a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases. The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network. For more information, please visit www.karolinskadevelopment.com . Attachment

Karolinska Development Investments

37 Investments

Karolinska Development has made 37 investments. Their latest investment was in Anacardio as part of their Unattributed on June 6, 2021.

CBI Logo

Karolinska Development Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/17/2021

Unattributed

Anacardio

Yes

1

3/27/2020

Unattributed

Svenska Vaccinfabriken Produktion

Yes

1

11/30/2018

Series C

Aprea Therapeutics

$56.79M

Yes

5AM Ventures, HealthCap Venture Capital, Redmile Group, Rock Springs Capital, Sectoral Asset Management, and Versant Ventures

2

2/26/2018

Series A

Subscribe to see more

$99M

Subscribe to see more

10

10/4/2017

Unattributed - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/17/2021

3/27/2020

11/30/2018

2/26/2018

10/4/2017

Round

Unattributed

Unattributed

Series C

Series A

Unattributed - II

Company

Anacardio

Svenska Vaccinfabriken Produktion

Aprea Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$56.79M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

5AM Ventures, HealthCap Venture Capital, Redmile Group, Rock Springs Capital, Sectoral Asset Management, and Versant Ventures

Sources

1

1

2

10

10

Karolinska Development Portfolio Exits

5 Portfolio Exits

Karolinska Development has 5 portfolio exits. Their latest portfolio exit was Aprea Therapeutics on October 03, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/3/2019

IPO

$991

6

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

10/3/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

IPO

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

6

10

10

10

10

Karolinska Development Acquisitions

1 Acquisition

Karolinska Development acquired 1 company. Their latest acquisition was Cogmed on August 13, 2006.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/13/2006

Acq - Fin

Acq - Fin

Date

8/13/2006

Investment Stage

Acq - Fin

Companies

Valuation

Total Funding

Note

Acq - Fin

Sources

Karolinska Development Fund History

3 Fund Histories

Karolinska Development has 3 funds, including Karolinska EIF Co-investment Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

11/20/2009

Karolinska EIF Co-investment Fund

Early-Stage Venture Capital

$53.28M

1

6/30/2006

Karolinska Development II

Subscribe to see more

$99M

10

8/14/2003

Karolinska Development I

Subscribe to see more

$99M

10

Closing Date

11/20/2009

6/30/2006

8/14/2003

Fund

Karolinska EIF Co-investment Fund

Karolinska Development II

Karolinska Development I

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Amount

$53.28M

$99M

$99M

Sources

1

10

10

Karolinska Development Partners & Customers

1 Partners and customers

Karolinska Development has 1 strategic partners and customers. Karolinska Development recently partnered with Karolinska Institutet on December 12, 2015.

Date

Type

Business Partner

Country

News Snippet

Sources

12/22/2015

Partner

Karolinska Institutet

Sweden

1

Date

12/22/2015

Type

Partner

Business Partner

Karolinska Institutet

Country

Sweden

News Snippet

Sources

1

Karolinska Development Team

9 Team Members

Karolinska Development has 9 team members, including current Chief Executive Officer, Viktor Drvota.

Name

Work History

Title

Status

Viktor Drvota

Chief Executive Officer

Current

Jim Van Heusden

Chief Executive Officer

Current

Torbjorn Bjerke

Chief Executive Officer

Former

Hans-Peter Ekre

Chief Executive Officer

Former

Jim Van heusden

Chief Executive Officer

Former

Name

Viktor Drvota

Jim Van Heusden

Torbjorn Bjerke

Hans-Peter Ekre

Jim Van heusden

Work History

Title

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

Status

Current

Current

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.